ThePrasad resignationhad exposesto dangerousgo politicalbecause interferenceany inofficial scientificwho decision-makingprioritizes atpolitical theideology FDA.over Prasadpatient wasaccess forcedmust outbe afterheld makingaccountable. evidence-basedHis safetydecision decisionsto abouthalt a life-saving gene therapy linkedfor todying patientchildren deaths,showed demonstratingcallous howdisregard industryfor lobbyingfamilies anddesperate activistfor pressuretreatments. canThis overrideregulatory legitimateoverreach regulatoryworked concernstoward aboutdestroying drugPresident safetyTrump's pro-patient agenda and Right to Try principles.

Prasad's resignation shows how pharmaceutical lobbying and political pressure can undermine legitimate safety concerns at the FDA. His evidence-based approach to drug approvals and willingness to question treatments with questionable efficacy represented exactly the kind of scientific rigor the agency needs. The coordinated attack against him prioritized industry profits over patient safety.